Rein Therapeutics (RNTX) Total Debt (2018)

Rein Therapeutics (RNTX) posted quarterly Total Debt of $5.3 million for Q4 2018, up 6.9% quarter-over-quarter from $5.0 million in Q3 2018.

Rein Therapeutics (RNTX) Total Debt (2018) Analysis & Trends

Rein Therapeutics (RNTX) has reported Total Debt for 1 consecutive years, with $5.3 million the latest figure, recorded in Q4 2018.

In Q4 2018, Total Debt changed N/A year-over-year to $5.3 million; the TTM figure through Dec 2018 stood at $5.3 million (changed N/A YoY), while the FY2018 annual figure was $5.3 million, changed N/A from the prior year.
Total Debt advanced to $5.3 million in Q4 2018 per RNTX's latest filing, from $5.0 million in the prior quarter.
Across five years, Total Debt topped out at $5.3 million in Q4 2018 and bottomed at $3.3 million in Q2 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	139.70 Bn	131.85 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.74 Bn	78.75 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	65.36 Bn	60.18 Bn	1.37 Bn	-
4	Moderna	59.15 Bn	54.01 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	42.12 Bn	37.02 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	31.88 Bn	28.57 Bn	992.69 Mn	-
7	BioNTech SE	28.14 Bn	9.75 Bn	668.28 Mn	770.36 Mn
8	Insmed	27.59 Bn	26.43 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.31 Bn	26.48 Bn	-	9.34 Bn
10	Rein Therapeutics	55.87 Mn	55.87 Mn	-	-

Download Data